Skip to content

Impact of the Intervention Timing of Plum - blossom Needle on the Efficacy of Peripheral Facial Paralysis in the Recovery Period

Impact of the Intervention Timing of Plum - blossom Needle on the Efficacy of Peripheral Facial Paralysis in the Recovery Period

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000369
Enrollment
Unknown
Registered
2025-02-19
Start date
2025-01-21
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

facial paralysis

Interventions

Experimental Group 1:The intervention timing of the plum - blossom needle ranges from 2 to 3 months
Experimental Group2:The intervention timing of the plum - blossom needle ranges from 3 to 6 months
control group:The intervention timing of the plum - blossom needle ranges from 7 days to 1 month

Sponsors

chenzhengyan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1)Meeting the diagnostic criteria of peripheral facial paralysis in both traditional Chinese medicine and Western medicine. (2) The age of the subjects is between 18 years old (inclusive) and 60 years old (inclusive). (3) First - onset disease with the disease course ranging from 7 days to 6 months (including the boundary values) and unilateral lesions at the affected site

Exclusion criteria

Exclusion criteria: Subjects with any of the following conditions should be excluded from the study: (1) Subjects with severe primary diseases of the kidneys, liver, endocrine system, hematopoietic system, etc., as well as those with mental illnesses. (2) Patients with facial paralysis caused by meningitis, Guillain - Barré syndrome, neuro - Lyme disease, posterior fossa tumors, otitis media, parotid gland diseases, trauma, diabetic peripheral neuropathy, etc. (3) Lactating, pregnant women, or women planning to become pregnant. (4) Subjects with contraindications to acupuncture, such as those with coagulation disorders like thrombocytopenia and hemophilia. (5) Subjects with local skin breakdown or infection. (6) Subjects who use other therapies or medications during the trial that may affect the determination of efficacy. (7) Any patients who cannot cooperate with the treatment. (8) Patients who are unwilling to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
House-Brackmann Facial Nerve Function Scale;

Secondary

MeasureTime frame
Facial Disability Index;House-Brackmann Grading Scale;

Countries

China

Contacts

Public Contactchenzhengyan

Wuxi Hospital of Traditional Chinese Medicine

1127730858@qq.com17714978832

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026